BioRestorative Therapies Partners with Leading Dermatologist Dr. David Goldberg to Advance Regenerative Aesthetics Platform
Key Insights
BioRestorative Therapies has formed a strategic partnership with internationally recognized dermatology leader Dr. David J. Goldberg (search) to conduct clinical validation studies for its regenerative BioCosmeceutical platform.
Dr. Goldberg will lead a prospective, controlled human clinical study evaluating the company's secretome-derived biologics (search) enriched with exosomes (search), growth factors (search), cytokines (search), and peptides (search) for skin appearance improvements.
The collaboration aims to generate publication-quality evidence supporting the platform's clinical role across professional and consumer applications while providing access to influential physician networks.
BioRestorative Therapies, Inc. (Nasdaq: BRTX) has announced a strategic partnership with David J. Goldberg (search), M.D., J.D., an internationally recognized leader in laser dermatology and regenerative aesthetics, to accelerate clinical validation and market adoption of its regenerative BioCosmeceutical platform. The collaboration establishes an independent clinical validation pathway while expanding access to influential physician networks across the aesthetic medicine landscape.
Clinical Study Design and Objectives
Dr. Goldberg will lead a prospective, controlled human clinical study designed to generate comparative outcome data evaluating improvements in skin appearance, texture, and overall quality relative to current aesthetic treatment benchmarks. The study will utilize BioRestorative's secretome-derived biologics (search), which are enriched with exosomes (search), growth factors (search), cytokines (search), and peptides (search), manufactured in the company's cGMP, ISO-7-certified cleanroom facility.
Results from the study are expected to support publication-quality evidence that further defines the platform's clinical role across both professional and consumer applications. This rigorous clinical framework aims to establish the level of evidence required to advance the regenerative aesthetics category responsibly.
Strategic Commercial Impact
"Dr. Goldberg's involvement materially strengthens both the scientific and commercial trajectory of our BioCosmeceutical platform," said Lance Alstodt, BioRestorative Therapies President, Chief Executive Officer and Chairman. "Our products are designed for use across professional, biologic dermal retail, and direct-to-consumer settings, and in each of those markets, independent clinical validation by a physician of his caliber is a meaningful differentiator."
The partnership provides direct access to physician networks and industry forums that drive adoption in regenerative aesthetics. Crystal Romano, Head of Global Commercialization at BioRestorative Therapies, emphasized that "Dr. Goldberg's leadership enables us to translate complex regenerative science into clinically validated, physician-endorsed solutions while strengthening our brand positioning across the aesthetic landscape."
Dr. Goldberg's Clinical Credentials and Network
Dr. Goldberg serves as Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai and Director of Cosmetic Dermatology and Clinical Research for the Schwieger Dermatology Group (search). He has authored more than 220 peer-reviewed publications and is widely regarded as a defining figure in modern dermatologic medicine with decades of leadership spanning clinical research, physician education, and the adoption of transformative aesthetic technologies.
As a pioneer in the clinical application of laser and energy-based aesthetic technologies, Dr. Goldberg founded several aesthetic meetings focusing on regenerative aesthetic dermatology, including the annual NJ New Frontiers in Cosmetic Medicine Meeting, the annual FL Aesthetic Extender Symposium, the annual Madrid, Spain 5 Continents Congress, and the upcoming Regenerative Aesthetic Dermatology Conference scheduled for June 2027 in Seattle, Washington.
Foundational Platform Strategy
The agreement with Dr. Goldberg represents the third pillar of a foundational triad that BioRestorative has been systematically assembling across its BioCosmeceutical platform. The first pillar involves manufacturing capability, established through the company's cGMP, ISO-7 certified cleanroom operations. The second pillar encompasses commercial execution, advanced through the recently announced collaboration with 203 Creates (search) to drive brand architecture and go-to-market strategy.
Together, these three pillars are anticipated to position BioRestorative with the manufacturing infrastructure, commercial architecture, and clinical validation required to compete in regenerative and aesthetics markets, whether through professional clinics and medspas or at-home consumer applications.
Conference Dissemination and Industry Impact
As part of the collaboration, Dr. Goldberg will present study findings, clinical data, and BioRestorative's technology and product platform at leading aesthetic and regenerative medicine conferences. This approach expands awareness among key opinion leaders and reinforces the company's positioning within the rapidly growing BioCosmeceutical market.
"BioRestorative's technology platform is grounded in an area of regenerative science with meaningful clinical promise," said Dr. Goldberg. "Rigorous human evaluation is essential to establishing the level of evidence this field requires. This collaboration provides an opportunity to assess these formulations through a structured clinical framework and to share those findings with the broader medical community."
Technology Platform Overview
BioRestorative's BioCosmeceutical platform features cell-based secretome enriched with exosomes (search), proteins, growth factors (search), peptides (search), and other carefully selected active ingredients. This proprietary biologic portfolio has been engineered to support skin health and longevity while addressing visible signs of aging and enhancing overall cosmetic performance.
The company believes that independent clinical validation combined with targeted physician engagement represents a critical driver of professional adoption, premium product positioning, and long-term recurring revenue potential in regenerative aesthetics. By integrating rigorous data generation, key opinion leader network access, and conference-level visibility with a multi-channel commercial strategy spanning clinics, medspas, biologic dermal retail, and direct-to-consumer markets, BioRestorative aims to establish the scientific and commercial infrastructure required to compete as a differentiated, evidence-based platform in the rapidly evolving regenerative aesthetics category.